BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 35456552)

  • 1. An Overview of siRNA Delivery Strategies for Urological Cancers.
    Halib N; Pavan N; Trombetta C; Dapas B; Farra R; Scaggiante B; Grassi M; Grassi G
    Pharmaceutics; 2022 Mar; 14(4):. PubMed ID: 35456552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential Application of Small Interfering RNA in Gastro-Intestinal Tumors.
    Losurdo P; de Manzini N; Palmisano S; Grassi M; Parisi S; Rizzolio F; Tierno D; Biasin A; Grassi C; Truong NH; Grassi G
    Pharmaceuticals (Basel); 2022 Oct; 15(10):. PubMed ID: 36297407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progress in Delivery of siRNA-Based Therapeutics Employing Nano-Vehicles for Treatment of Prostate Cancer.
    Ashrafizadeh M; Hushmandi K; Rahmani Moghadam E; Zarrin V; Hosseinzadeh Kashani S; Bokaie S; Najafi M; Tavakol S; Mohammadinejad R; Nabavi N; Hsieh CL; Zarepour A; Zare EN; Zarrabi A; Makvandi P
    Bioengineering (Basel); 2020 Aug; 7(3):. PubMed ID: 32784981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strategies to optimize siRNA delivery to hepatocellular carcinoma cells.
    Scarabel L; Perrone F; Garziera M; Farra R; Grassi M; Musiani F; Russo Spena C; Salis B; De Stefano L; Toffoli G; Rizzolio F; Tonon F; Abrami M; Chiarappa G; Pozzato G; Forte G; Grassi G; Dapas B
    Expert Opin Drug Deliv; 2017 Jun; 14(6):797-810. PubMed ID: 28266887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strategies for Delivery of siRNAs to Ovarian Cancer Cells.
    Farra R; Maruna M; Perrone F; Grassi M; Benedetti F; Maddaloni M; El Boustani M; Parisi S; Rizzolio F; Forte G; Zanconati F; Cemazar M; Kamensek U; Dapas B; Grassi G
    Pharmaceutics; 2019 Oct; 11(10):. PubMed ID: 31652539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Smart siRNA delivery systems based on polymeric nanoassemblies and nanoparticles.
    Tamura A; Nagasaki Y
    Nanomedicine (Lond); 2010 Sep; 5(7):1089-102. PubMed ID: 20874023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strategies for in vivo delivery of siRNAs: recent progress.
    Higuchi Y; Kawakami S; Hashida M
    BioDrugs; 2010 Jun; 24(3):195-205. PubMed ID: 20462284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Environment-Responsive Lipid/siRNA Nanoparticles for Cancer Therapy.
    Lu ZR; Laney VEA; Hall R; Ayat N
    Adv Healthc Mater; 2021 Mar; 10(5):e2001294. PubMed ID: 33615743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pre-Clinical and Clinical Applications of Small Interfering RNAs (siRNA) and Co-Delivery Systems for Pancreatic Cancer Therapy.
    Mirzaei S; Gholami MH; Ang HL; Hashemi F; Zarrabi A; Zabolian A; Hushmandi K; Delfi M; Khan H; Ashrafizadeh M; Sethi G; Kumar AP
    Cells; 2021 Nov; 10(12):. PubMed ID: 34943856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significance and applications of nanoparticles in siRNA delivery for cancer therapy.
    Ali HM; Urbinati G; Raouane M; Massaad-Massade L
    Expert Rev Clin Pharmacol; 2012 Jul; 5(4):403-12. PubMed ID: 22943120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipid-based nanoparticles for siRNA delivery in cancer therapy: paradigms and challenges.
    Gomes-da-Silva LC; Fonseca NA; Moura V; Pedroso de Lima MC; Simões S; Moreira JN
    Acc Chem Res; 2012 Jul; 45(7):1163-71. PubMed ID: 22568781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanoparticles-Based Strategies to Improve the Delivery of Therapeutic Small Interfering RNA in Precision Oncology.
    Huang J; Xiao K
    Pharmaceutics; 2022 Jul; 14(8):. PubMed ID: 36015212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanotechnology-Based siRNA Delivery Systems to Overcome Tumor Immune Evasion in Cancer Immunotherapy.
    Deng K; Yang D; Zhou Y
    Pharmaceutics; 2022 Jun; 14(7):. PubMed ID: 35890239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. siRNA delivery systems for cancer treatment.
    Oh YK; Park TG
    Adv Drug Deliv Rev; 2009 Aug; 61(10):850-62. PubMed ID: 19422869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RNAi-based therapeutics and tumor targeted delivery in cancer.
    Kara G; Calin GA; Ozpolat B
    Adv Drug Deliv Rev; 2022 Mar; 182():114113. PubMed ID: 35063535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and Delivery of Therapeutic siRNAs: Application to MERS-Coronavirus.
    Sohrab SS; El-Kafrawy SA; Mirza Z; Kamal MA; Azhar EI
    Curr Pharm Des; 2018; 24(1):62-77. PubMed ID: 29119921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polyethylenimines for RNAi-mediated gene targeting in vivo and siRNA delivery to the lung.
    Günther M; Lipka J; Malek A; Gutsch D; Kreyling W; Aigner A
    Eur J Pharm Biopharm; 2011 Apr; 77(3):438-49. PubMed ID: 21093588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simultaneous nanocarrier-mediated delivery of siRNAs and chemotherapeutic agents in cancer therapy and diagnosis: Recent advances.
    Bidar N; Darroudi M; Ebrahimzadeh A; Safdari M; de la Guardia M; Baradaran B; Goodarzi V; Oroojalian F; Mokhtarzadeh A
    Eur J Pharmacol; 2022 Jan; 915():174639. PubMed ID: 34919890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current progress of siRNA/shRNA therapeutics in clinical trials.
    Burnett JC; Rossi JJ; Tiemann K
    Biotechnol J; 2011 Sep; 6(9):1130-46. PubMed ID: 21744502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent Advances in siRNA Delivery Systems for Prostate Cancer Therapy.
    Aghamiri S; Raee P; Shahmohamadnejad S; Shabani S; Ghorbani J; Sameni M; Ebrahimi MT
    Curr Pharm Biotechnol; 2022; 23(4):579-593. PubMed ID: 34132181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.